Everett H Meyer, MD
Hematopoietic Cell Transplantation and Cellular Therapy · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Adventist Health Ukiah Valley · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Meyer’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A109097 · Current
Licensed to practise in California · since 2009 · expires 2027-01-31 · Stanford University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Adventist Health Ukiah ValleyUkiah, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Adventist Health, which runs 28 hospitals in 3 statesPatients rate it 3 of 5 · 66% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Rate of emergency department (ED) visits for patients receiving outpatient chemotherapy: 7.9 (5.8 to 10.5) · 253 cases, Jan 2024 – Dec 2024
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Adventist Health Ukiah Valley
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 0 better, 4 the same, 0 worse of 4 measures. Readmissions: 0 better, 8 the same, 0 worse of 8 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 7.9 (5.8 to 10.5) · 253 cases | Worse | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.92 (0 to 1.95) · 319 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.92 (0.51 to 1.32) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.3 · 38 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.9 · 137 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.4 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.3 · 74 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 647 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.42) · 2,093 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.29 (0.08 to 0.51) · 2,081 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.64 (2.23 to 7.05) · 328 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.2) · 99 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.45 (0.79 to 4.11) · 309 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.96 (0 to 15.74) · 117 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.32 (2.24 to 10.4) · 103 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.67 (0.18 to 3.17) · 119 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.29 (0 to 1.2) · 1,614 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.891 | No different | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.607 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.396 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 114 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -0.9 · 171 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 6.5 · 270 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.1 · 234 cases | None | Jul 2023 – Jun 2025 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.4 (8 to 13.6) · 253 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 37 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.5 (10.4 to 17.4) · 1,320 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.4) · 361 cases | No different | Jan 2024 – Dec 2024 |
What patients said (341 patients answered, 15% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 76% |
| Doctors "always" communicated well | 78% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 75% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 62% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 72% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 33% |
| "YES", patients would definitely recommend the hospital | 66% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$32,034
Medicare paid this office $32,034 for 63 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 29 | $15,755 | $106 |
| Long return visit (40+ min) | 14 | $4,790 | $126 |
| Long return visit (40+ min) | 14 | $3,982 | $173 |
Who their Medicare patients are
63 Original Medicare patients in 2024. Average age 70 · Women 46% · Also on Medicaid 18% · Health risk score 3.54. Above the middle of the specialty; the typical hematopoietic cell transplantation and cellular therapy clinician is at 2.85.
Conditions among them: High blood pressure 63% · Chronic kidney disease 33% · Atrial fibrillation 25% · Diabetes 22% · Depression 21% · Coronary heart disease 19%.
The office billed $116,462, Medicare allowed $40,393 and paid $32,034; for 281 services of 9 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 63 | 281 | 70 | 3.54 | $116,462 | $32,034 |
| 2023 | 50 | 131 | 69 | 3.44 | $47,801 | $13,728 |
| 2022 | 22 | 53 | 66 | 3.69 | $22,735 | $5,893 |
| 2021 | 61 | 248 | 67 | 3.67 | $104,017 | $25,227 |
| 2020 | 57 | 185 | 66 | 3.66 | $117,908 | $18,743 |
| 2019 | 51 | 288 | 67 | 3.80 | $100,092 | $26,870 |
| 2018 | 44 | 157 | 66 | 3.20 | $39,773 | $14,035 |
| 2017 | 66 | 216 | 64 | 3.32 | $83,092 | $20,066 |
| 2016 | 46 | 205 | 64 | 3.16 | $79,770 | $18,897 |
| 2015 | 40 | 118 | 65 | 3.60 | $42,576 | $11,028 |
| 2014 | 43 | 209 | 62 | 3.07 | $71,491 | $19,941 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 2 services
| Long return visit (40+ min) | 26 | $5,585 | $127 |
| Return visit (30+ min) | 13 | $1,445 | $85 |
2022: 1 service
| Long return visit (40+ min) | 12 | $1,738 | $134 |
2021: 3 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 14 | $11,673 | $94 |
| Long return visit (40+ min) | 29 | $6,501 | $123 |
| Return visit (30+ min) | 31 | $4,411 | $85 |
2020: 3 services
| Long return visit (40+ min) | 36 | $10,170 | $105 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 14 | $4,664 | $97 |
| Return visit (30+ min) | 13 | $1,296 | $65 |
2019: 3 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 25 | $18,179 | $93 |
| Long return visit (40+ min) | 15 | $3,635 | $98 |
| Return visit (30+ min) | 19 | $1,579 | $58 |
2018: 2 services
| Long return visit (40+ min) | 20 | $3,612 | $88 |
| Return visit (30+ min) | 20 | $2,701 | $69 |
2017: 3 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 28 | $7,765 | $90 |
| Long return visit (40+ min) | 20 | $4,531 | $96 |
| Return visit (30+ min) | 24 | $3,294 | $67 |
2016: 3 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 25 | $13,283 | $92 |
| Long return visit (40+ min) | 11 | $1,852 | $88 |
| Return visit (30+ min) | 12 | $988 | $55 |
2015: 2 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 15 | $5,122 | $93 |
| Long return visit (40+ min) | 16 | $3,868 | $97 |
2014: 2 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 24 | $12,292 | $92 |
| Long return visit (40+ min) | 12 | $3,947 | $99 |
Medicaid work
$5,643 in 2024
Medicaid paid $5,643 for 82 billed services this clinician did in 2024, up to 15 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 82 | $5,643 |
| 2024 | 82 | 1 | 15 | $5,643 |
| 2021 | 16 | 1 | 12 | $1,713 |
| 2020 | 44 | 1 | 16 | $2,012 |
See the largest Medicaid services in earlier years
2021
| Long return visit (40+ min) | 16 | $1,713 |
2020
| Long return visit (40+ min) | 44 | $2,012 |
Drugs they prescribed that Part D paid
$1,040,887
Pharmacies billed $1,040,887 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 293) in 2024. At or below the middle of the specialty; the typical hematopoietic cell transplantation and cellular therapy clinician is at 3%.
220 generic and 73 brand-name prescriptions · $1,040,887 in drug cost · 80 antibiotic prescriptions to 18 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Jakafi | 30 | $457,467 | $15,249 |
| Imbruvica | 20 | $199,678 | $9,984 |
| Tacrolimus | 22 | $971 | $44 |
| Acyclovir | 31 | $756 | $24 |
| Sulfamethoxazole-Trimethoprim | 54 | $426 | $8 |
See all 8 drugs
| Jakafi | 30 | $457,467 | $15,249 |
| Imbruvica | 20 | $199,678 | $9,984 |
| Tacrolimus | 22 | $971 | $44 |
| Acyclovir | 31 | $756 | $24 |
| Sulfamethoxazole-Trimethoprim | 54 | $426 | $8 |
| Dexamethasone | 14 | $261 | $19 |
| Ciprofloxacin | 13 | $32 | $2 |
| Fluconazole | 11 | $4 | $0 |
Year by year
| 2024 | 293 | 33 | 0% (0) | 25% | $1,040,887 |
| 2023 | 168 | 21 | 0% (0) | 18% | $399,972 |
| 2022 | 104 | 17 | 0% (0) | 26% | $225,888 |
| 2021 | 300 | 28 | None | 19% | $454,693 |
| 2020 | 284 | 23 | 0% (0) | 15% | $239,368 |
| 2019 | 370 | 37 | 0% (0) | 13% | $360,156 |
| 2018 | 356 | 23 | None | 17% | $534,684 |
| 2017 | 410 | 24 | None | None | $346,212 |
| 2016 | 242 | 25 | None | 7% | $110,356 |
| 2015 | 257 | 21 | 0% (0) | None | $28,348 |
| 2014 | 197 | 29 | None | 13% | $50,440 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 5 drugs
| Jakafi | 13 | $214,546 | $16,504 |
| Imbruvica | 11 | $124,903 | $11,355 |
| Tacrolimus | 15 | $1,137 | $76 |
| Acyclovir | 19 | $664 | $35 |
| Sulfamethoxazole-Trimethoprim | 37 | $410 | $11 |
2022: 3 drugs
| Imbruvica | 24 | $174,913 | $7,288 |
| Acyclovir | 49 | $1,230 | $25 |
| Tacrolimus | 11 | $256 | $23 |
2021: 7 drugs
| Imbruvica | 35 | $221,947 | $6,341 |
| Jakafi | 15 | $208,144 | $13,876 |
| Tacrolimus | 26 | $1,787 | $69 |
| Acyclovir | 64 | $1,675 | $26 |
| Fluconazole | 11 | $458 | $42 |
| Sulfamethoxazole-Trimethoprim | 30 | $398 | $13 |
| Prednisone | 27 | $285 | $11 |
2020: 6 drugs
| Jakafi | 12 | $117,047 | $9,754 |
| Tacrolimus | 20 | $1,819 | $91 |
| Acyclovir | 72 | $1,570 | $22 |
| Prednisone | 37 | $512 | $14 |
| Sulfamethoxazole-Trimethoprim | 17 | $173 | $10 |
| Penicillin V | 13 | $157 | $12 |
2019: 10 drugs
| Jakafi | 12 | $127,116 | $10,593 |
| Acyclovir | 83 | $1,638 | $20 |
| Tacrolimus | 28 | $1,528 | $55 |
| Prednisone | 23 | $272 | $12 |
| Ondansetron | 14 | $208 | $15 |
| Levofloxacin | 13 | $190 | $15 |
| Sulfamethoxazole-Trimethoprim | 17 | $169 | $10 |
| Ranitidine | 17 | $168 | $10 |
| Famotidine | 14 | $124 | $9 |
| Penicillin V | 11 | $121 | $11 |
2018: 11 drugs
| Noxafil | 21 | $127,730 | $6,082 |
| Rydapt | 11 | $101,524 | $9,229 |
| Tacrolimus | 25 | $1,780 | $71 |
| Acyclovir | 46 | $981 | $21 |
| Gabapentin | 20 | $270 | $14 |
| Prednisone | 21 | $232 | $11 |
| Sulfamethoxazole-Trimethoprim | 16 | $170 | $11 |
| Famotidine | 21 | $156 | $7 |
| Pantoprazole | 17 | $131 | $8 |
| Lorazepam | 15 | $74 | $5 |
| Amlodipine Besylate | 11 | $47 | $4 |
2017: 12 drugs
| Jakafi | 16 | $231,480 | $14,467 |
| Tacrolimus | 40 | $1,963 | $49 |
| Fluocinonide | 18 | $1,764 | $98 |
| Acyclovir | 43 | $812 | $19 |
| Fluconazole | 11 | $579 | $53 |
| Prednisone | 34 | $255 | $7 |
| Sulfamethoxazole-Trimethoprim | 35 | $192 | $5 |
| Gabapentin | 16 | $177 | $11 |
| Pantoprazole | 16 | $176 | $11 |
| Montelukast | 12 | $162 | $14 |
| Famotidine | 25 | $144 | $6 |
| Amlodipine Besylate | 15 | $59 | $4 |
2016: 4 drugs
| Tacrolimus | 26 | $2,052 | $79 |
| Acyclovir | 29 | $584 | $20 |
| Famotidine | 16 | $213 | $13 |
| Sulfamethoxazole-Trimethoprim | 24 | $122 | $5 |
2015: 9 drugs
| Tacrolimus | 16 | $1,325 | $83 |
| Mycophenolate Mofetil | 12 | $1,245 | $104 |
| Acyclovir | 24 | $403 | $17 |
| Valacyclovir | 12 | $357 | $30 |
| Prednisone | 16 | $286 | $18 |
| Azithromycin | 12 | $136 | $11 |
| Montelukast | 11 | $121 | $11 |
| Sulfamethoxazole-Trimethoprim | 20 | $114 | $6 |
| Famotidine | 13 | $106 | $8 |
2014: 3 drugs
| Acyclovir | 25 | $483 | $19 |
| Ciprofloxacin | 12 | $130 | $11 |
| Amlodipine Besylate | 13 | $48 | $4 |
Money from drug and device companies
$2,103,458 in 2021
A payment is not proof that care is biased.
| Grifols S.A. | None | $2,103,458 | 1 payment
|
See the published payment
| Grifols S.A. | Consulting · 2021-03-16 | None | $2,103,458 |
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Incyte Corporation · A Randomized, Double Blind, Placebo Controlled Phase 3 Study of Itacitinib Or Placebo in Combination With Corticosteroids for the Treatment of First Line Acute Graft Versus Host Disease · 2019 | Their institution | $58,546 |
| Incyte Corporation · A Randomized, Double Blind, Placebo Controlled Phase 3 Study of Itacitinib Or Placebo in Combination With Corticosteroids for the Treatment of First Line Acute Graft Versus Host Disease · 2020 | Their institution | $24,089 |
| Incyte Corporation · A Single Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid Refractory Acute Graft Versus Host Disease · 2019 | Their institution | $3,426 |
| Incyte Corporation · Prospective, Longitudinal, Non Interventional Study of Disease Burden and Treatment of Patients With Low Risk Myelofibrosis (Mf) Or High Risk Essential Thrombocythemia (Et) Or Et Patients Receiving Et Directed Therapy · 2020 | Their institution | $2,151 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1508013517
- Licence
- CA A109097California A109097: Current · expires 2027-01-31
- Trained
- Stanford University School of Medicine, 2008
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A869820
- Taxonomy
- Federal specialty code 207RH0000X (207RH0000X); Federal specialty code 207RH0003X (207RH0003X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2008-08-20
- NPI last updated
- 2024-04-15
- NPI record certified
- 2024-04-15
This is when the NPI record was last certified, not a medical board exam.